ROR1 TriKE

ROR1 TriKE is an investigational **tri-specific natural killer cell engager biologic** from GT Biopharma designed for cancer immunotherapy. It belongs to the company's TriKE platform, which uses an NK-cell engaging construct to redirect and activate NK cells against **receptor tyrosine kinase-like orphan receptor 1** expressing tumor cells. Based on the provided context, the program has been developed primarily for **prostate cancer** and potentially other **ROR1-overexpressing solid tumors**, with preclinical data showing enhanced NK-cell mediated cytotoxicity, NK-cell activation, and interferon gamma production. The asset appears to have been in **preclinical IND-enabling development** with a goal of advancing into early-phase clinical testing.

Other names

ROR1-targeting Tri-specific Killer EngagerROR-1-targeting Tri-specific Killer EngagerROR 1-targeting Tri-specific Killer EngagerROR1-targeting TriKEROR-1-targeting TriKEROR 1-targeting TriKE